GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evelo Biosciences Inc (OTCPK:EVLO) » Definitions » ROA %

Evelo Biosciences (Evelo Biosciences) ROA % : -238.65% (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Evelo Biosciences ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Evelo Biosciences's annualized Net Income for the quarter that ended in Sep. 2023 was $-49.46 Mil. Evelo Biosciences's average Total Assets over the quarter that ended in Sep. 2023 was $20.72 Mil. Therefore, Evelo Biosciences's annualized ROA % for the quarter that ended in Sep. 2023 was -238.65%.

The historical rank and industry rank for Evelo Biosciences's ROA % or its related term are showing as below:

EVLO' s ROA % Range Over the Past 10 Years
Min: -175.81   Med: -89.95   Max: -55.92
Current: -175.81

During the past 7 years, Evelo Biosciences's highest ROA % was -55.92%. The lowest was -175.81%. And the median was -89.95%.

EVLO's ROA % is ranked worse than
91.84% of 1557 companies
in the Biotechnology industry
Industry Median: -35.2 vs EVLO: -175.81

Evelo Biosciences ROA % Historical Data

The historical data trend for Evelo Biosciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evelo Biosciences ROA % Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROA %
Get a 7-Day Free Trial -55.92 -68.16 -103.18 -136.88 -150.38

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -123.34 -124.90 -190.51 -268.88 -238.65

Competitive Comparison of Evelo Biosciences's ROA %

For the Biotechnology subindustry, Evelo Biosciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evelo Biosciences's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evelo Biosciences's ROA % distribution charts can be found below:

* The bar in red indicates where Evelo Biosciences's ROA % falls into.



Evelo Biosciences ROA % Calculation

Evelo Biosciences's annualized ROA % for the fiscal year that ended in Dec. 2022 is calculated as:

ROA %=Net Income (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=-114.527/( (87.871+64.441)/ 2 )
=-114.527/76.156
=-150.38 %

Evelo Biosciences's annualized ROA % for the quarter that ended in Sep. 2023 is calculated as:

ROA %=Net Income (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=-49.456/( (20.819+20.627)/ 2 )
=-49.456/20.723
=-238.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2023) net income data. ROA % is displayed in the 30-year financial page.


Evelo Biosciences  (OTCPK:EVLO) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-49.456/20.723
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-49.456 / 0)*(0 / 20.723)
=Net Margin %*Asset Turnover
=N/A %*0
=-238.65 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Evelo Biosciences ROA % Related Terms

Thank you for viewing the detailed overview of Evelo Biosciences's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Evelo Biosciences (Evelo Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
620 Memorial Drive, 5th Floor, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.
Executives
Simba Gill director, officer: President & CEO 515 GALVESTON DR, REDWOOD CITY CA 94063
Mark Bodmer officer: See Remarks C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Marella Thorell officer: Chief Financial Officer 1226 CHARTER LANE, AMBLER PA 19002
Duncan Mchale officer: Chief Medical Officer C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Alexander C Reynolds director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Horizon Technology Finance Corp 10 percent owner 312 FARMINGTON AVENUE, FARMINGTON CT 06032
Jeffrey R. Moore director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Robert L. Rosiello director 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Stephen J Carriere officer: Principal Accounting Officer
David R Epstein director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Lord Ara Darzi director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Pioneering Fund Vii, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Tonya Williams director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139